Merck & Co Inc
NYSE: MRK
$96.31
-$2.05 (-2.1%)
Closing Price on November 15, 2024
MRK Articles
Chevron, DuPont, Merck, and Cisco weighed on the DJIA Tuesday.
Published:
Last Updated:
Apple, DuPont, Merck, and Verizon lead DJIA higher on Friday.
Published:
Last Updated:
Chevron, Merck, Exxon, and McDonald's kept the DJIA above water on Wednesday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of the Dow Jones Industrial Average companies scheduled to report their quarterly results this week.
Published:
Last Updated:
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The March 31 short interest data have been compared with the previous figures, and short interest decreased in most of these selected pharmaceutical stocks.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
Published:
Last Updated:
24/7 Wall St. has taken a look at a few companies within the health care sector that might have seen a reaction from the health care vote in Congress, or lack thereof.
Published:
Last Updated:
DuPont, Chevron, Merck, and Pfizer sink the DJIA on Thursday.
Published:
Last Updated:
Intel, GE, Merck, and Chevron weighed on the DJIA Monday.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Chevron, Verizon, Pfizer, and Merck combined to weigh on the DJIA Tuesday.
Published:
Last Updated:
Merck and Pfizer each saw their shares sink early on Monday after the firms gave an update on their type 2 diabetes treatment.
Published:
Last Updated:
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
Published:
Last Updated:
Merck saw its shares slip on Wednesday after the firm reported that it will be halting its mid-to-late-stage clinical trial for the treatment of Alzheimer’s disease.
Published:
Last Updated: